Daljeet Kohli of India-Nivesh Securities is of the view that Cadila Healthcare may test Rs 913. "This is a story for another 1-1.5 years where we will see the company going back to the normal trajectory of 20 plus margins and that will result in re-rating of the stock," Kohli said.
first published: Dec 24, 2013 03:26 pm
A collection of the most-viewed Moneycontrol videos.
This Tenant Moved from a 100sqft Slum to a Premium Residence | The Tenant
Live: Nifty snaps 4-day winning streak but rises 1% this week | Closing Bell
Live: Can Bihar poll outcome trigger Nifty to reclaim 26,000-mark? | Opening Bell
Live: Nifty holds above 25,900 but off nearly 100 pts from day's high | Closing Bell
